Consumer staples are considered safe havens in turbulent markets due to their inelastic demand profiles. Unfortunately, the sector hasn’t provided much protection lately as it pulled back by 9.7% over the past six months. This drop was worse than the S&P 500’s 2% loss.
Let’s dig into the relative performance of The Honest Company (NASDAQ:HNST) and its peers as we unravel the now-completed Q4 personal care earnings season.
Health and wellness products company USANA Health Sciences (NYSE:USNA)
will be announcing earnings results tomorrow afternoon. Here’s what investors should know.
Fragrance and perfume company Inter Parfums (NASDAQ:IPAR)
will be announcing earnings results tomorrow after market close. Here’s what you need to know.
All three major U.S. indices are red in Wednesday's midday trading as investors weighed President Donald Trump's proposed tariffs on auto imports, pharmaceuticals and semiconductors.
Wellness company Medifast (NYSE:MED) beat Wall Street’s revenue expectations in Q4 CY2024, but sales fell by 37.7% year on year to $119 million. On the other hand, next quarter’s revenue guidance of $110 million was less impressive, coming in 15.9% below analysts’ estimates. Its GAAP profit of $0.07 per share was significantly above analysts’ consensus estimates.
What a brutal six months it’s been for Medifast. The stock has dropped 20.6% and now trades at $19.84, rattling many shareholders. This may have investors wondering how to approach the situation.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at personal care stocks, starting with Medifast (NYSE:MED).
Wellness products company Nature’s Sunshine Products (NASDAQ:NATR)
will be reporting earnings tomorrow after market hours. Here’s what investors should know.
Wellness company Medifast (NYSE:MED) reported Q3 CY2024 results exceeding the market’s revenue expectations, but sales fell 40.6% year on year to $140.2 million. On the other hand, next quarter’s revenue guidance of $110 million was less impressive, coming in 16.4% below analysts’ estimates. Its GAAP profit of $0.10 per share was also 153% above analysts’ consensus estimates.
